Human CK-17/KRT17 (Cytokeratin 17) CLIA Kit (HUES01104)
- SKU:
- HUES01104
- Product Type:
- ELISA Kit
- ELISA Type:
- CLIA Kit
- Size:
- 96 Assays
- Sensitivity:
- 18.75pg/mL
- Range:
- 31.25-2000pg/mL
- ELISA Type:
- Sandwich
- Reactivity:
- Human
- Sample Type:
- Serum, plasma and other biological fluids
Description
Product Name: | Human CK-17/KRT17 (Cytokeratin 17) CLIA Kit |
SKU: | HUES01104 |
Target: | Human CK-17/KRT17 (Cytokeratin 17) |
Size: | 96T |
Assay type: | Sandwich |
Assay time: | 4.5h |
Sensitivity: | 18.75 pg/mL |
Detection range: | 31.25-2000 pg/mL |
Kit component: |
|
This CLIA kit uses the Sandwich-CLIA principle. The micro CLIA plate provided in this kit has been pre-coated with an antibody specific to Human CK17/KRT17. Standards or samples are added to the micro CLIA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human CK17/KRT17 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human CK17/KRT17, biotinylated detection antibody and Avidin-HRP conjugate will appear fluorescence. The Relative light unit (RLU) value is measured by the Chemiluminescence immunoassay analyzer. The RLU value is positively associated with the concentration of Human CK17/KRT17. You can calculate the concentration of Human CK17/KRT17 in the samples by comparing the RLU value of the samples to the standard curve.
Linearity: |
| ||||||||||||||||||||||||||||||||||||||||||
Recovery: |
| ||||||||||||||||||||||||||||||||||||||||||
Precision: |
|
Sample type &Sample volume: | Serum, plasma and other biological fluids; 100μL |
Reproducibility: | Both intra-CV and inter-CV are < 15%. |
Application: | This CLIA kit applies to the in vitro quantitative determination of Human CK17/KRT17 concentrations in Serum, plasma and other biological fluids. |
Specificity: | This kit recognizes Human CK17/KRT17 in samples. No significant cross-reactivity or interference between Human CK17/KRT17 and analogues was observed. |